Penicillamine 125 mg/5 mL Oral Liquid is a custom-prepared medication designed to facilitate ease of administration and ensure precise dosing for patients who may have difficulty swallowing tablets or capsules, such as children and the elderly. This aqueous solution allows for the active ingredient, Penicillamine, to be delivered in a 5 mL volume containing 125 mg of the drug, which can be easily measured and ingested.

Penicillamine is a chelating agent used primarily in the treatment of Wilson's disease, a rare genetic disorder that causes excessive accumulation of copper in the body, leading to hepatic and neurological complications. By binding to copper, Penicillamine facilitates its excretion and helps in reducing the toxic effects of copper overload. Additionally, Penicillamine is indicated for the management of cystinuria, an inherited condition that leads to the formation of cystine stones in the kidneys, bladder, and ureters. It works by reducing cystine levels in the urine, thereby decreasing the likelihood of stone formation.

Moreover, Penicillamine has immunomodulatory properties and is used in the treatment of rheumatoid arthritis, where it helps to alleviate symptoms by reducing inflammation and slowing down disease progression. It is important to note that Penicillamine treatment requires careful monitoring due to potential side effects, including hypersensitivity reactions, renal impairment, and hematological disorders. Regular laboratory tests are recommended to monitor the patient's response to therapy and to detect any adverse effects promptly.

For prescribers considering Penicillamine 125 mg/5 mL Oral Liquid, it is essential to provide comprehensive patient education regarding the correct administration of the liquid formulation, adherence to dosing schedules, and the importance of consistent monitoring. Patients should be informed about the potential side effects and instructed to report any unusual symptoms to their healthcare provider immediately. As compounding pharmacists at Bayview Pharmacy, we are committed to ensuring the highest quality of our formulations and are available to answer any questions or concerns regarding this medication. Please feel free to reach out to us for further information or guidance on the use of Penicillamine 125 mg/5 mL Oral Liquid.

Penicillamine is a chelating agent used in the treatment of Wilson's disease, a rare genetic disorder that causes copper accumulation in the body, leading to liver and neurological damage. It is also used for rheumatoid arthritis to reduce inflammation and pain, and in certain cases, it is used to treat cystinuria, a condition that leads to the formation of cystine kidney stones. Penicillamine works by binding to metals and other substances in the body for removal or to reduce their effects.

When considering the use of Penicillamine 125 mg/5 mL Oral Liquid, it is important to be aware of potential drug interactions that may affect the efficacy of the medication or increase the risk of adverse effects. Penicillamine should not be used concomitantly with gold therapy, antimalarial or cytotoxic drugs, oxyphenbutazone, phenylbutazone, or other drugs that may cause bone marrow suppression, due to the increased risk of hematological reactions.

Iron and other minerals such as magnesium and aluminum can reduce the absorption of penicillamine. Therefore, the use of iron supplements, antacids, or mineral-containing multivitamins should be separated by at least two hours from the administration of penicillamine. Additionally, penicillamine can increase the requirements for pyridoxine (vitamin B6), so supplementation may be necessary during treatment.

Patients receiving penicillamine should avoid concurrent use of ACE inhibitors as this combination has been associated with an increased risk of severe reactions, including anaphylactoid reactions. The use of penicillamine with other drugs that can cause bone marrow suppression or affect blood cell counts, such as certain chemotherapy agents, should be closely monitored by a healthcare provider.

Penicillamine may also interact with digoxin, leading to reduced absorption of digoxin and potentially subtherapeutic levels. Patients on both medications should have their digoxin levels monitored and may require a dosage adjustment. Additionally, penicillamine can reduce the levels of phenytoin in the blood, and patients taking both medications should be monitored for reduced efficacy of phenytoin.

It is also important to note that penicillamine can cause a false-positive test for urinary ketones and may interfere with measurements of urinary glucose using copper sulfate reagents. Patients with diabetes should be aware of this potential interference with their glucose monitoring.

Patients should be advised to report any signs of adverse reactions, such as rash, fever, mouth ulcers, sore throat, unusual bruising or bleeding, muscle weakness, or difficulty breathing, as these may be indicative of serious side effects or interactions. Regular monitoring of blood counts, renal function, and liver enzymes is recommended during treatment with penicillamine.

As with any medication, it is crucial to inform healthcare providers of all medications, supplements, and over-the-counter drugs being taken to avoid potential interactions. If you have any questions or concerns regarding the use of Penicillamine 125 mg/5 mL Oral Liquid or its interactions with other medications, please reach out to us at Bayview Pharmacy for further assistance.

Penicillamine is a chelating agent that has multiple therapeutic uses, including the treatment of Wilson's disease, rheumatoid arthritis, and certain conditions that cause excess copper accumulation in the body. As a 125 mg/5 mL oral liquid, this formulation is designed to provide a precise dose of penicillamine in a form that is easier to swallow than solid dosage forms, making it particularly suitable for patients who have difficulty swallowing pills, such as children and the elderly.

The mechanism by which penicillamine works is multifaceted. In Wilson's disease, penicillamine binds to copper, which accumulates excessively due to a genetic disorder affecting copper metabolism. The drug forms a stable complex with copper, which is then excreted from the body, thereby reducing copper levels and alleviating symptoms. In rheumatoid arthritis, penicillamine is believed to reduce inflammation and slow down disease progression, although its exact mechanism of action in this condition is not fully understood. It may involve the reduction of certain immune cells and the suppression of collagen cross-linking, which can contribute to joint damage.

When using penicillamine, it is important to adhere to the prescribed dosage and administration guidelines, as the therapeutic window is narrow and the potential for adverse effects is significant. Monitoring of blood counts, renal function, and liver enzymes is recommended during treatment. Patients should be advised to report any signs of adverse reactions, such as skin rash, difficulty breathing, or changes in urine color, to their healthcare provider immediately.

For prescribers considering this formulation, it is crucial to assess the patient's overall health status, including any pre-existing liver or kidney conditions, as these may affect the drug's metabolism and excretion. Additionally, penicillamine should be used with caution in patients with a history of penicillin allergy, as cross-reactivity may occur. The oral liquid formulation allows for flexible dosing adjustments and can be particularly beneficial for titrating the dose to the patient's response and tolerance.

If you have any questions about this formulation or its use in treating specific disease states, please do not hesitate to reach out to us at Bayview Pharmacy. Our team of compounding pharmacists is here to provide you with the information and support you need to ensure safe and effective treatment for your patients.

Aside from its primary use in treating diseases like Wilson's disease, rheumatoid arthritis, and cystinuria, Penicillamine has been observed to be useful in a variety of other conditions due to its chelating and immunomodulatory effects. Penicillamine can chelate copper, lead, mercury, and other toxic metals, and may therefore be employed in cases of heavy metal poisoning. It binds to the metals, facilitating their excretion from the body. Penicillamine has also been used in conditions like systemic sclerosis (scleroderma) and in certain cases to prevent kidney stone formation.

Some studies have explored the use of Penicillamine in delaying the progression of certain chronic kidney diseases, where its property to reduce collagen crosslinking may play a therapeutic role. However, its use in other conditions should be approached with caution, considering its potential side effects and the availability of more effective treatments for some of these conditions. It is important to note that any off-label uses should be explored under close supervision by a healthcare provider, who can weigh the risks and benefits for the individual patient.

Additionally, it's worth mentioning that while the oral liquid formulation of Penicillamine may improve adherence for those who have difficulty swallowing pills, it's important for prescribers and patients to ensure that the liquid formulation is compatible with the patient's other medications and dietary restrictions, as the liquid base may contain ingredients that could interact with other substances. The flavoring agents used in the liquid preparation may also be a consideration for people with certain allergies or sensitivities. For any further information about the specific uses of Penicillamine 125 mg/5 mL Oral Liquid, or if you have questions about this medication, please do not hesitate to reach out to us. We are here to ensure that you and your patients receive comprehensive and tailored pharmaceutical care.